From China to the US, we keep working to make the world a healthier place.
Dr. James Dewey Watson, world-renowned molecular biology scientist, geneticist, and one of the leaders of molecular biology in the 20th century. In 1953, he and Francis Crick discovered the double helixstructure of DNA (including the central dogma). In 1962, Watson shared the Nobel Prize in Physiology or Medicine with Crick and Maurice Wilkins.
The discovery of the double helix structure of DNA is one of the most important scientific discoveries in the 20th century, an important milestone in the history of science. Together with natural selection, it unifies the concept of biology and marks the birth of molecular genetics. Watson, who was only 25 years old at the time, became a celebrity scientist.
Dr. Watson also played an important leading role in the Human Genome Project, the Moon Shot Project of life sciences, which was completed at the beginning of the 21st century after more than a decade’s hard work. For the first time in human history, we obtained our own “Book of Life”.
From 1968 to 2007, Watson served as the director/chancellor of Cold Spring Harbor Laboratory, leading it to become one of the best research centers in the world. In 2012, Watson was named one of the 20 Most Influential Figures in American History by Time Magazine. In 2012, Watson was named one of the 20 Most Influential Figures in American History by Time Magazine
At the advanced age of over 90, Dr. Watson’s last wish in life is to fight and win the War On Cancer. To this day, he still keeps on reading and thinking, and studies new therapeutic technologies diligently. In collaboration with Cheerland, Dr. Watson hopes to bring affordable cancer drugs to the people of China and the world.
Founder of Cheerland Investment Group and Cheerland Biomedicine, Mr. Liu has over 20 years of experiences in capital investment and business operations in China and abroad. He has established several successful companies in various industries in China and the US, and has successfully led many cross-border and cross-market transformations of the companies he founded. He has a Master’s degree in Business Operations from Nanyang Technological University, Singapore.
Renowned financier and entrepreneur, Dr. Ma is currently the chairman of the board of directors of the Shenzhen International Public Welfare Institute, the executive director of the Chinese Finance Society, and the executive director of the Chinese Business Leaders’ Association. Former President of China Merchants Bank; Chairman of the National Science and Technology Achievement Transformation Guidance Fund, and other important positions. On Fortune’s “2012 China’s 50 Most Influential Business Leaders” list, Dr. Ma ranked 35th. He holds a Ph.D. in Economics from Southwestern University of Finance and Economics, and an Honorary Doctorate degree from the University of Southern California.
With 25 years of experiences in international biotech & CDMO, Mr. Garvey held various executive, technical, and operational leadership positions in biopharmaceutical companies in the U.S., Asia, and Europe. He served as Global Head of Technical Operations, BeiGene; a founding Executive member and Vice President of Samsung Biologics Manufacturing, where he helped design, validate, technology transfer, operate, and successfully licensed an impressive +14 novel medicines in the largest Drug Substance facility (362,000L of capacity) in a single location; and various technical and management positions at global pharmaceutical companies such as Takeda, Sanofi and Genentech.
Managing over a billion dollars of AUM for Cheerland’s overseas investment arm based in New York City, Ms. Liu led/participated in dozens of investment deals in both real estate and biotech in the past several years. She holds M.S. and B.S. degrees in Business Management from the University of Edinburgh, UK.
Mr. Li has more than 30 years of experience with multinational companies serving different senior management roles. Prior to Cheerland, he served as China General Manager of a leading global CDMO company, where he applied advanced technology and CDMO management processes to the China market, achieving significant business growth and successful operations of its biologics services for both domestic and international clients. He has also spent 8 years in a leading global life science company as Senior Director of Service Operations, and subsequently Vice President of Commercial Operations, for its China operations.
A Collaborative Regulatory Affairs and Quality leader with over 20 years of broad expertise in biologics development and large-scale, global manufacturing, Dr. Fernandez served as Senior Director of Global Regulatory Affairs, Samsung Biologics; Associate Director of Global Regulatory Affairs, Shire / Baxalta / Baxter Healthcare. He holds a Ph.D. in analytical chemistry from University of California.
With extensive biotech commercialization experiences, Mr. Li served as Deputy Director of the National Engineering Research Center, as well as executives positions at Roche and Baiyunshan Pharmaceutical. At Roche, he developed the first standard unit for molecular testing of hepatitis C, and the world’s first fully automatic instrument for quantitative diagnosis of viruses, which has contributed to developing new diagnostic methods for AIDS and hepatitis C. He holds an MS from Sun Yat-sen University, and MBA from Michigan University.
Mr. Zhang has 20 years of experience in various engineering areas, including 9 years in project management in the pharmaceutical industry. He has served in different capacities for industry leaders including Shenhua Group, Tianjin Bohai Oil Marine Engineering & Supply, TSKF-GSK, Cockram (Shanghai) Construction, GE Healthcare Tianjin, Baxter China, and most recently BeiGene Guangzhou. He obtained his Bachelor of Mechanical & Electrical Engineering degree from Hebei University of Technology.
Currently Chairman and Chief Scientist of Jiangsu Antai Biotechnology, he was a professor at the Fourth Military Medical University; Director of the Reproductive Health Quality Control Center of the National Family Planning Commission; Executive Vice Chairman of the China Reproductive Health Products Standardization Committee; Director of Therapeutic Cell Vaccine Engineering Research Center, Jiangsu Province. He was one of the pioneers in China in the research and development and industrialization of gene diagnosis, biochip and cell targeted therapy technology. Authored 22 patens and published more than 300 papers, as well as 6 books.
Dr. Zhou is currently Professor in medical cell biology at Shenzhen University. He has published over 60 papers in the areas of stem cells, disease mechanisms and regeneration of musculoskeletal and nervous systems. He also serves as an executive member of several national academic societies in musculoskeletal diseases and anti-aging research. His work has been supported by major national and international funding agencies including NSFC, MOST, Scoliosis Research Society, and Research Grant Council Hong Kong. Dr. Zhou is also a co-founder for several biotech start-ups developing advanced innovative therapy and medicine products and services.
CLBiomed just moved into its new headquarter in the first building of the still under-construction Cheerland Watson Center for Life Sciences and Technology, in May 2020. Sitting between priceless ocean view and rolling green hills, it awaits the next breakthrough in biomedicine.
2020: New Milestone, New Journey
The Cheerland Watson Center upon completion
Officially opened on May 18, 2020
Cheerland Team Building
The Next-generation of Cheerlander